These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 30762712

  • 1. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Blakeway EA, Elshimy N, Muinonen-Martin A, Marples M, Mathew B, Mitra A.
    Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712
    [Abstract] [Full Text] [Related]

  • 2. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K, McGettigan S, Elenitsas R, Chu EY.
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [Abstract] [Full Text] [Related]

  • 3. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S, Ieremia E, Matin RN.
    Eur J Dermatol; 2019 Jun 01; 29(3):349-351. PubMed ID: 31389799
    [No Abstract] [Full Text] [Related]

  • 4. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
    Marano AL, Clarke JM, Morse MA, Shah A, Barrow W, Selim MA, Hall RP, Cardones AR.
    Br J Dermatol; 2019 Sep 01; 181(3):580-583. PubMed ID: 30244487
    [Abstract] [Full Text] [Related]

  • 5. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S, Nguyen R, Opie JM, Andrews MC.
    Australas J Dermatol; 2017 Aug 01; 58(3):e109-e112. PubMed ID: 27170423
    [Abstract] [Full Text] [Related]

  • 6. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
    Woodbeck R, Metelitsa AI, Naert KA.
    Am J Dermatopathol; 2018 Jul 01; 40(7):523-526. PubMed ID: 29924748
    [Abstract] [Full Text] [Related]

  • 7. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM.
    Melanoma Res; 2018 Dec 01; 28(6):645-647. PubMed ID: 30256271
    [Abstract] [Full Text] [Related]

  • 8. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
    Andersson NW, Zachariae C, Simonsen AB.
    Eur J Cancer; 2021 Mar 01; 145():168-170. PubMed ID: 33486439
    [No Abstract] [Full Text] [Related]

  • 9. Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.
    Wang LL, Patel G, Chiesa-Fuxench ZC, McGettigan S, Schuchter L, Mitchell TC, Ming ME, Chu EY.
    JAMA Dermatol; 2018 Sep 01; 154(9):1057-1061. PubMed ID: 30027278
    [Abstract] [Full Text] [Related]

  • 10. Cutaneous Eruption Secondary to Immunotherapy for Metastatic Melanoma Limited to Sites of Locoregional Melanoma Metastases: A Possible Variant of Locus Minoris Resistentiae.
    Donaldson M, Owen JL, Choi JN.
    JAMA Dermatol; 2018 Jul 01; 154(7):846-847. PubMed ID: 29800007
    [No Abstract] [Full Text] [Related]

  • 11. Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.
    Nardin C, Borot S, Beaudoin MA, Cattin F, Puzenat E, Gauthier AS, Schillo F, Borg C, Aubin F.
    Invest New Drugs; 2019 Apr 01; 37(2):375-377. PubMed ID: 30145624
    [Abstract] [Full Text] [Related]

  • 12. Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab.
    Ogawa-Momohara M, Muro Y, Goto K, Obuse C, Satoh M, Kono M, Akiyama M.
    J Dermatol; 2020 Jun 01; 47(6):e217-e219. PubMed ID: 32173880
    [No Abstract] [Full Text] [Related]

  • 13. Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade.
    Mauzo SH, Tetzlaff MT, Nelson K, Amaria R, Patel S, Aung PP, Nagarajan P, Torres-Cabala CA, Diab A, Prieto VG, Curry JL.
    Int J Dermatol; 2019 Sep 01; 58(9):1045-1052. PubMed ID: 29152725
    [Abstract] [Full Text] [Related]

  • 14. Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern.
    Trinidad C, Nelson KC, Glitza Oliva IC, Torres-Cabala CA, Nagarajan P, Tetzlaff MT, Ivan D, Hwu WJ, Prieto VG, Curry JL, Aung PP.
    J Cutan Pathol; 2018 Jul 01; 45(7):504-507. PubMed ID: 29633300
    [Abstract] [Full Text] [Related]

  • 15. Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
    Mochel MC, Ming ME, Imadojemu S, Gangadhar TC, Schuchter LM, Elenitsas R, Payne AS, Chu EY.
    J Cutan Pathol; 2016 Sep 01; 43(9):787-91. PubMed ID: 27161449
    [Abstract] [Full Text] [Related]

  • 16. PD-1 inhibitor induced alopecia areata.
    Guidry J, Brown M, Medina T.
    Dermatol Online J; 2018 Dec 15; 24(12):. PubMed ID: 30677804
    [Abstract] [Full Text] [Related]

  • 17. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.
    Gambichler T, Doerler M, Scheel CH.
    Lupus; 2021 Mar 15; 30(3):531-533. PubMed ID: 33407044
    [No Abstract] [Full Text] [Related]

  • 18. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
    Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.
    Eur J Cancer; 2017 Nov 15; 86():37-45. PubMed ID: 28961465
    [Abstract] [Full Text] [Related]

  • 19. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Nguyen BH, Kuo J, Budiman A, Christie H, Ali S.
    Melanoma Res; 2017 Apr 15; 27(2):152-154. PubMed ID: 27776019
    [Abstract] [Full Text] [Related]

  • 20. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
    Berger M, Legeay AL, Souci S, Streichenberger N, Thomas L, Dalle S.
    Eur J Cancer; 2018 Nov 15; 104():227-230. PubMed ID: 30322679
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.